EverSource Wealth Advisors LLC Has $285,000 Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

EverSource Wealth Advisors LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,350 shares of the medical research company’s stock after purchasing an additional 70 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in IQVIA were worth $285,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares in the last quarter. Morningstar Investment Services LLC raised its holdings in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after purchasing an additional 606,333 shares during the period. Capital Research Global Investors lifted its stake in IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after purchasing an additional 592,372 shares during the last quarter. 1832 Asset Management L.P. grew its holdings in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter worth approximately $70,610,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price for the company. Barclays upped their price objective on shares of IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group started coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price for the company. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Morgan Stanley boosted their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $267.00.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.5 %

IQV stock opened at $239.57 on Wednesday. The company has a market cap of $43.67 billion, a PE ratio of 32.73, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The business has a 50-day simple moving average of $241.03 and a 200 day simple moving average of $233.69.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.22 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.